Magna-Lab ( OTCMKTS:MAGAA ) and AxoGen ( NASDAQ:AXGN ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.
Analyst Recommendations
Get Magna-Lab alerts: This is a summary of recent ratings and target prices for Magna-Lab and AxoGen, as reported by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Magna-Lab 0 0 0 0 N/A AxoGen 0 1 3 0 2.75 AxoGen has a consensus target price of $41.33, suggesting a potential upside of 102.52%.
Insider & Institutional Ownership
89.1% of AxoGen shares are owned by institutional investors. 15.3% of Magna-Lab shares are owned by company insiders. Comparatively, 7.9% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Magna-Lab and AxoGen’s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Magna-Lab N/A N/A -$140,000.00 N/A N/A AxoGen $83.94 million 9.47 -$22.40 million ($0.54) -37.80 Magna-Lab has higher earnings, but lower revenue than AxoGen.
Volatility and Risk
Magna-Lab has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.
Profitability
This table compares Magna-Lab and AxoGen’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Magna-Lab N/A N/A -2,673.68% AxoGen -26.68% -15.77% -13.75% Summary
Magna-Lab beats AxoGen on 5 of the 9 factors compared between the two stocks.
Magna-Lab Company Profile
Magna-Lab, Inc. is a shell company, which intends to identify and merge with an operating company. The company was founded by Lawrence A. Minkoff on February 22, 1991 and is headquartered in Syosset, NY.
AxoGen Company Profile
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Magna-Lab Magna-Lab
